FUBO vs CURI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

FUBO

67.0
AI Score
VS
FUBO Wins

CURI

41.6
AI Score

Investment Advisor Scores

FUBO

67score
Recommendation
BUY

CURI

42score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric FUBO CURI Winner
Revenue 4.60B 38.41M FUBO
Net Income -16.30M 7.55M CURI
Net Margin -0.4% 19.7% CURI
Operating Income -56.02M 7.64M CURI
ROE -2.0% 18.2% CURI
ROA -0.4% 11.2% CURI
Total Assets 3.94B 67.47M FUBO
Cash 230.28M 5.38M FUBO
Current Ratio 1.00 0.78 FUBO

Relative Price Performance (Last 90 Days)

FUBO 1M: -19.8% · 3M: -5.8% CURI 1M: -2.8% · 3M: +16.8%

Current Technical Phase

FUBO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.2%), weak momentum, RSI 36

RSI (14): 36.0 · Price: $8.12

CURI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 48.4 · Price: $2.78

Fundamentals Snapshot

Metric FUBO CURI
Market Cap — —
Forward P/E 18.0 9.0
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.4% 0.2%
Gross Margin 0.1% 0.6%
Operating Margin 0.0% 0.4%
EPS -1.24 0.00
Dividend Yield — 0.13%

Frequently Asked Questions

Based on our detailed analysis, FUBO is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.